Multivariate logistic regression analysis of factors influencing sustained virological response.

<p>Multivariate logistic regression analysis of factors influencing sustained virological response.</p

Proportion of patients with hemoglobin decline ≤ 3 mg/l or > 3 mg/l in groups of increasing mean serum ribavirin concentrations.

<p>Proportion of patients with hemoglobin decline ≤ 3 mg/l or > 3 mg/l in groups of increasing mean serum ribavirin concentrations.</p

Patient characteristics and SVR rates.

<p>Patient characteristics and SVR rates.</p

Patient characteristics and SVR rates for HCV Genotypes 2 and 3.

<p>Patient characteristics and SVR rates for HCV Genotypes 2 and 3.</p

Total viremic cases (blue) and associated healthcare costs (red), by year, 1950–2050 (the upper and lower bounds represent 95% uncertainty intervals).

<p>Total viremic cases (blue) and associated healthcare costs (red), by year, 1950–2050 (the upper and lower bounds represent 95% uncertainty intervals).</p

Projected base and hybrid scenario results for cirrhosis, decompensated cirrhosis and HCC, 1950–2050.

<p>Projected base and hybrid scenario results for cirrhosis, decompensated cirrhosis and HCC, 1950–2050.</p

Persons who do not inject drugs (non-PWID) versus persons who inject drugs (PWID) among foreign-born persons in the national surveillance data of the Federal Office of Public Health, by country of origin and age (please note the different y-axis scale for Italy).

<p>Persons who do not inject drugs (non-PWID) versus persons who inject drugs (PWID) among foreign-born persons in the national surveillance data of the Federal Office of Public Health, by country of origin and age (please note the different y-axis scale for Italy).</p

Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.

<p>(* Base costs were calculated as described above, ** Low costs represent the minimum cost associated with each stage, *** High costs represent the maximum cost associated with disease each stage).</p><p>Estimated cost per patient per year (excluding the cost of antiviral therapy), by disease stage, in 2011 Euros.</p

Ratio of proportions in the Swiss Hepatitis C Cohort Study (SCCS) respectively in cases mandatorily reported to the Federal Office of Public Health (FOPH) compared to the proportion in the general population, by country of birth/origin and age group.

<p>Ratio of proportions in the Swiss Hepatitis C Cohort Study (SCCS) respectively in cases mandatorily reported to the Federal Office of Public Health (FOPH) compared to the proportion in the general population, by country of birth/origin and age group.</p

Exploratory scenario outputs, 2013–2030.

<p>(A) HCV-related liver-related deaths, by scenario; (B) Maximum number of patients treated annually to achieve 50% or 90% reduction, by METAVIR stage treated; (C) Impact of treatment restrictions (restriction to ≥F3 or F4) on a strategy to reduce liver-related mortality by 90%, and the annual number of patients treated before ‘running out of patients’; (D) Impact of 2-year and 5-year delays on a strategy to reduce liver-related mortality by 90%.</p